Guided Therapeutics (GTHP) & Its Peers Head to Head Survey

Guided Therapeutics (OTCMKTS:GTHP) is one of 70 publicly-traded companies in the “Electromedical equipment” industry, but how does it contrast to its peers? We will compare Guided Therapeutics to similar businesses based on the strength of its profitability, earnings, institutional ownership, valuation, risk, analyst recommendations and dividends.

Analyst Ratings

This is a summary of current recommendations for Guided Therapeutics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guided Therapeutics	0	0	0	0	N/A
Guided Therapeutics Competitors	259	780	1923	59	2.59

As a group, “Electromedical equipment” companies have a potential upside of 3,172.71%. Given Guided Therapeutics’ peers higher possible upside, analysts clearly believe Guided Therapeutics has less favorable growth aspects than its peers.

Insider and Institutional Ownership

9.7% of Guided Therapeutics shares are held by institutional investors. Comparatively, 44.2% of shares of all “Electromedical equipment” companies are held by institutional investors. 66.8% of Guided Therapeutics shares are held by insiders. Comparatively, 13.6% of shares of all “Electromedical equipment” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Guided Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Guided Therapeutics	N/A	N/A	-138.23%
Guided Therapeutics Competitors	-350.61%	-97.06%	-31.48%

Risk and Volatility

Guided Therapeutics has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, Guided Therapeutics’ peers have a beta of 18.38, meaning that their average share price is 1,738% more volatile than the S&P 500.

Earnings and Valuation

This table compares Guided Therapeutics and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Guided Therapeutics	$100,000.00	-$3.49 million	-5.35
Guided Therapeutics Competitors	$1.06 billion	$91.09 million	-7.94

Guided Therapeutics’ peers have higher revenue and earnings than Guided Therapeutics. Guided Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

Guided Therapeutics peers beat Guided Therapeutics on 6 of the 10 factors compared.

About Guided Therapeutics

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.